Results 111 to 120 of about 72,847 (303)

Derived cannabinoid product availability among online vape shops

open access: yesPreventive Medicine Reports
Objectives: To determine the proportion of online vape shops that offer derived cannabinoid products in a large metropolitan area (San Diego, California), measure their compliance with state hemp regulations, and estimate whether these shops receive more
Nora Satybaldiyeva   +7 more
doaj   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer   +16 more
wiley   +1 more source

Pharmacokinetics of Cannabinoids

open access: yesPain Research and Management, 2005
Delta‐9‐tetrahydrocannabinol (Δ‐9‐THC) is the main psychoactive ingredient of cannabis (marijuana). The present review focuses on the pharmacokinetics of THC, but also includes known information for cannabinol and cannabidiol, as well as the synthetic marketed cannabinoids, dronabinol (synthetic THC) and nabilone.
openaire   +3 more sources

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka   +6 more
wiley   +1 more source

The psychometric properties of validated tools to assess cannabis use disorder: A systematic review and meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung   +8 more
wiley   +1 more source

Antitumoral effects of cannabis in Notch1‐mutated T‐cell acute lymphoblastic leukemia

open access: yesCancer Communications, 2023
Elazar Besser   +9 more
doaj   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

open access: yesAddiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin   +3 more
wiley   +1 more source

BIOCHEMICAL PROFILE OF BIOTIN‐ANANDAMIDE, A NOVEL TOOL FOR THE VISUALIZATION OF ANANDAMIDE ACCUMULATION

open access: yes, 2008
Anandamide (arachidonoylethanolamide, AEA) acts as endogenous agonist of both cannabinoidand vanilloid receptors. During the last two decades, its metabolic pathways and biologicalactivity have been extensively investigated and relatively well ...
Maccarrone M   +7 more
core   +1 more source

Urinary Δ9-tetrahydrocannabinol and metabolite concentrations following cannabis use: A systematic review

open access: yesPharmacological Research
Urine testing is used in a variety of contexts to identify cannabis use. Most tests target 11-nor-9-carboxy-Δ⁹-tetrahydrocannabinol (11-COOH-THC), the terminal metabolite of Δ⁹-tetrahydrocannabinol (THC), the principal intoxicant in cannabis.
Danielle McCartney   +5 more
doaj   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

open access: yesAddiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Home - About - Disclaimer - Privacy